Answers are grounded in this paper and cite their sources.
Thyroid cancers are often considered the “darling” form of cancer as the 5-year survival rate for non-recurrent well differentiated thyroid carcinoma are some of the highest amongst malignancies. However, the advanced and aggressive forms of thyroid carcinoma are rare and aggressive. For advanced medullary thyroid cancer (MTC), radioactive iodine-refractory differentiated thyroid cancer (DTC), and anaplastic thyroid cancer, there were limited options before the advent of new targeted and biologic therapies. Tyrosine kinase inhibitors (TKIs) and multikinase inhibitors (MKIs) inactivate cell proliferation signals in these cancers and show promise in slowing disease progression of these more aggressive subtypes of thyroid cancer. In addition, several new small-molecule therapies are being developed which are increasingly specific to certain subsites involved in cell proliferation. With the advent of precision-based medicine, these new tools will treat patients based on their tumor’s genetic profile on an individualized basis to improve overall survival of these patients. We discuss the successes, failures, and current investigations into the biologic treatments of this more aggressive group of thyroid cancers.
No takes yet. Share an insight, caveat, or question.
Britt et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: